

The logo for REVA Medical, featuring the word "REVA" in a stylized, outlined font. The letters are white with a thin blue outline, set against a background of abstract, flowing blue and green smoke-like patterns.

REVA

# REVA Medical

Corporate Presentation  
January 2018

# Important Notice

## **Not an Offer for Securities**

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial product advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of the Company and conduct its own investigations and analysis.

## **Information is a Synopsis Only**

This presentation only contains a synopsis of information on the Company and, accordingly, no reliance may be placed for any purpose whatsoever on the sufficiency or completeness of such information. Information presented in this presentation is subject to change without notice and REVA does not have any responsibility or obligation to inform you of any matter arising or coming to their notice after the date of this presentation, which may affect any matter in the presentation.

## **Forward-Looking Statements**

This presentation contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding our plans to commence commercial operations and sell products, conduct clinical trials, develop pipeline products, incur losses from operations, list our securities for sale on a U.S. stock exchange, and assess and obtain future financings for operating and capital requirements. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 28, 2017, and as may be updated in our periodic reports thereafter. Any forward-looking statements in this presentation speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

## **Disclaimer**

This presentation and any supplemental materials have been prepared by the Company based on available information. The information contained in this presentation is an overview and does not contain all information necessary to make an investment decision. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. To the maximum extent permitted by law, none of the Company, or any of its members, directors, officers, employees, or agents or advisers, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of the Company or any of its directors, officers, employees, or agents.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.



**REVA Medical is a leader in bioresorbable polymer technologies for vascular applications**


**Launching a proprietary product for  
Coronary Artery Disease and  
pursuing Peripheral Artery Disease therapies**

# REVA's Disruptive Technology

## Proprietary Bioresorbable Polymer Technology

- Bioresorbable polycarbonate polymers derived from naturally occurring tyrosine amino acid
- Covalently bound iodine for radiopacity
- 19 biomaterial polymer families with international patent protection
- Capability to tailor the polymer properties to the clinical application by modifying:
  - Strength
  - Flexibility
  - Degradation time
  - Drug delivery profile


## Vascular Applications



# REVA's First Application: Fantom<sup>®</sup> Bioresorbable Scaffold for Coronary Artery Disease

**FIRST** and **ONLY** Bioresorbable Scaffold Made with Tyrocore<sup>™</sup>

## Fantom Features




### **STRONG**

Large expansion range and maintains vessel patency



### **FLEXIBLE**

Deliverability and single-step inflation



### **BIOCOMPATIBLE**

Vessel healing and restoration



### **RADIOPAQUE**

Procedural accuracy and ease-of-use


## Tyrocore<sup>™</sup>

- Proprietary bioresorbable polymer
- Patent protected through 2029
- Derived from naturally occurring tyrosine amino acid
- Uniquely designed for vascular scaffolds
- Manufactured in-house

# The Problem: Coronary Artery Disease

Cardiovascular Disease is the leading cause of death globally<sup>1</sup>


- Coronary Artery Disease (CAD) is the most common type of heart disease
- CAD occurs when a build-up of plaque in a coronary artery blocks the flow of blood to the heart muscle
- Treatments for CAD aim to restore blood flow through the blocked artery



<https://www.cdc.gov/heartdisease/facts.htm>


# Evolution of Treatments of CAD

## History of rapid innovation



# Global Coronary Stent Market

## Large and Profitable



### WW Market Share


Abbott (Xience Sierra)	34%
Boston Scientific (Synergy)	32%
Medtronic (Resolute Oynx)	27%
Other	7%

“The good news about those [CRM and stent] businesses is, they are **extremely profitable and they generate high cash flows.**” Miles White, CEO Abbott, Q2 2017 Earnings Call



# Large and Rapid Market Share Disruptions with New Technology Introductions


**Innovation Matters:  
Current players not focused on R&D creating opening for companies with a disruptive innovation**



# Next Innovation: Bioresorbable Scaffolds

Driven by limitations of current standard of care

- DES are associated with long term complications
- DES can limit future treatment options including coronary artery bypass, CT's, and MRI's




TLF = cardiac death, target vessel MI, ischemic-driven TLR


# What is a Bioresorbable Scaffold?

- Temporary implantable device restores blood flow to diseased arteries
- Provides radial support to artery during healing process
- Elutes drug to limit excess tissue formation
- Encapsulates within vessel wall
- Dissolves from the body over time and restores natural vessel motion


**Restores Blood Flow**



**Supports Vessel Healing**



**Dissolves and Restores Motion**



# The Appeal of a Bioresorbable Scaffold

## Value to Physician and Patient

- Preserves maximum flexibility for future treatment options (bypass grafting, MRI, CT)
- Allows artery to return to its natural state to restore freedom of movement
- May reduce the rate of future clinical events



***“The ideal of a stent that does its job and disappears is a valuable long-term goal, especially in young patients with long life-expectancy.”***

EuroPCR 2017 course director Dr. William Wijns

***“I think it’s not at all inconceivable to think that a better device... ..will allow what will hopefully be shown to be long-term advantages of no longer having the permanent metal frame in the vessel...”***


Gregg Stone, MD, New-York Presbyterian/Columbia University quoted in [tctmd.com](http://tctmd.com)<sup>1</sup>

# Fantom Bioresorbable Scaffold

## Combines Novel Polymer with Established Drug and Design


### Tyrocore™

- Radiopaque
- Provides strength during critical vessel healing period
- Restores natural vessel motion in one year
- Complete resorption with benign degradants
- Proprietary to REVA



### Sirolimus


- First anti-proliferative agent used in drug eluting stents
- Highly lipophilic with broad therapeutic window
- Demonstrated across multiple clinical studies and drug eluting stents



(c) molekuul www.fotosearch.com


### Scaffold Design

- Balloon expandable ring-and-link structure
- Unique design for each diameter (2.5, 3.0, and 3.5 mm)
- Large expansion range




### Delivery System

- Non-compliant nylon balloon
- High 18 atm rated burst pressure
- Rapid exchange



# Fantom Offers Substantial Improvement Over 1<sup>st</sup> Generation BRS

	<b>Fantom</b>	<b>Absorb</b>
Material	<b>Tyrocore™</b>	PLLA
Strut thickness <sup>1</sup>	<b>125 μm</b>	157 μm
Strength <sup>2</sup>	<b>0.22 N/mm</b>	0.14 N/mm
Radiopacity	<b>Yes</b>	No



- Competitors have struggled to show improved long term safety
- Physicians are seeking improvements in 2nd generation devices
  - Thinner, more deliverable, easier to use; no compromise on strength
  - Improved safety

# Fantom Clinical Performance

## Excellent Clinical Performance through 24 Months

		12 Months	24 Months
<b>FANTOM</b> (n=240)	FANTOM II <sup>1</sup> <i>Major Adverse Cardiac Events/"MACE"</i>	<b>4.2%</b>	<b>5.6%</b> (preliminary results for 125 patients)
<b>ABSORB</b> (n=1,322)	ABSORB III <i>Target Lesion Failure/"TLF"</i>	7.8% <sup>2</sup>	11.0% <sup>3</sup>
<b>XIENCE</b> (n=686)	ABSORB III <i>Target Lesion Failure/"TLF"</i>	6.1% <sup>2</sup>	7.9% <sup>3</sup>

1) Hermiller, J. Fantom: A Radio-Opaque "Stent-Like" BRS with Improved Expansion Characteristics. Presented TCT 2017. 2) Ellis S, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *NEJM* 2015;373:1905-15. 3) Ellis S, Kereiakes, D. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent: ABSORB III. Presented ACC 2017.

# Demonstrated Low Scaffold Thrombosis

## Strong Performance through 24 Months

	<b>Fantom</b> (n=240)	<b>Absorb</b> (n=1,322)	<b>Xience DES</b> (n=686)
Study	FANTOM II <sup>1</sup>	ABSORB III	ABSORB III
<b>Scaffold Thrombosis</b>			
<b>Acute</b> (0 to 1 day)	0%	0.15% <sup>2</sup>	0.58% <sup>2</sup>
<b>Subacute</b> (2 to 30 days)	0.4%	0.91% <sup>2</sup>	0.15% <sup>2</sup>
<b>Late</b> (31 to 365 days)	0%	0.46% <sup>2</sup>	0% <sup>2</sup>
<b>Very Late</b> (>365 days)	1 event (preliminary results for 125 patients)	0.3% <sup>3</sup>	0% <sup>3</sup>

All 240 patients beyond 18 months - 125 patients beyond 24 months of follow-up

1) Hermiller, J. Fantom: A Radio-Opaque “Stent-Like” BRS with Improved Expansion Characteristics. Presented TCT 2017. 2) Ellis S, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *NEJM* 2015;373:1905-15. 3) Ellis S, Kereiakes, D. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent: ABSORB III. Presented ACC 2017.



# Pipeline Development: Fantom Global Clinical Program

## Enrollment Complete – In Follow Up

FANTOM I First-in-human safety study (n=7)   Year 3

FANTOM II Cohorts A&B Multi-center safety and performance study (n=240)   Year 2

## Enrolling

FANTOM II Cohort C Long lesion and multiple vessel, multi-center study (n=50)  enrolling

FANTOM STEMI Single center pilot study in STEMI (n=20)  enrolling


## Planning

FANTOM Registry European post-market multi-center registry (n=125+)  planning

FANTOM III (US pivotal trial) Multi-center RCT vs. metallic DES (n=1,800-2,200)   planning


FANTOM Japan (pivotal trial) Multi-center RCT vs. metallic DES (n=350-400)  planning

# Targeted Launch Underway in Europe



# Attractive Market Opportunity with Manageable Investment

Gross Revenue Potential in Phase 1<sup>1</sup>



## SHARE GROWTH DRIVERS

- Clinical experience
- New product launch
- Indication expansion: long lesion, multi-vessel, AMI

## 150 Target Accounts

### PHASE 1

- **\$36 million** revenue potential with 20% share
- Direct sales with **6** reps

### PHASE 2

- Potential to double Phase 1 gross revenue
- Areas of interest:
  - Italy, Spain, Brazil, Middle East, Eastern Europe
- Sales through distributors

# Long Term Growth Strategy

## WIN IN CORONARY

### Geographic Growth

- European countries
- Countries that accept CE Mark
- New approvals, e.g. Brazil, Japan, US

### Product Improvements

- Fantom Encore: next generation with thinner struts
- New sizes including longer lengths and larger diameters

### Indication Expansion

- Long lesions
- Multi-vessel disease
- Acute myocardial infarction

## INVEST IN PERIPHERAL

### Clinical Evaluation

- Pursue below the knee CE Mark with current platform
- Assess product performance

### Polymer R&D


- Invest in development of novel polymers specifically designed for peripheral artery applications

### Develop New Products

- Introduce unique scaffolds for below the knee and above the knee revascularization

# Innovating to Build a \$1+ Billion Company


## Coronary Revenue Potential




Revenue calculation assumes 20% market share and \$1,000 ASP

## + Peripheral Market Opportunity

### BELOW THE KNEE



### ABOVE THE KNEE



Sources: Coronary Market Potential estimate calculations: DRG MedTech 360 Market Report IC Devices Europe, June 2015; Peripheral Market Opportunity

© 2017 REVA Medical. estimate calculations: BTK: Nehler M, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. JVS 2014.; ATK: Murabito J, et al. Temporal trends in the incidence of intermittent claudication from 1950-99. AJE 2005.; Population data from United Nations online database.

# Strong IP Portfolio

## Patents Extending 2029-2034

- 19 biomaterial polymer families with international patent protection
- Fantom polymer protected through 2029
- Fantom polymer manufacturing developed in-house by REVA Medical and protected as trade secret
- Patents cover multiple medical applications including vascular scaffolds, embolics, orthopedics, and drug delivery

# Experienced Management Team

**Reggie Groves**

CHIEF EXECUTIVE OFFICER



McKinsey & Company



HARVARD  
BUSINESS SCHOOL

**Brandi Roberts**

CHIEF FINANCIAL OFFICER



$\alpha$   
Alphatec Spine



**Jeffrey Anderson,**

SVP, CLINICAL AND REGULATORY AFFAIRS

neomend



**Richard Kimes**

SVP, OPERATIONS



GUIDANT

**Carmelo Mastrandrea**

VP, EUROPE



BIOTRONIK

GUIDANT

**Joann Yao**

SR. DIR., GLOBAL MARKETING



Boston  
Scientific


# Upcoming Milestones

## CLINICAL PROGRAM

- FANTOM II 24-month data release, H1 2018
- Expanded indication acute results, 2018
- US IDE study approval, anticipated 2018

## PRODUCT DEVELOPMENT

- CE Mark for Fantom Encore 95 micron 2.5 mm diameter scaffold, H1 2018
- Launch Fantom Encore broader matrix, 2018
- CE Mark for Fantom in below-the-knee application, 2018





# REVA Investment Highlights

## DISRUPTIVE TECHNOLOGY

- Proprietary bioresorbable polymer technologies for vascular applications
- Strong IP Patent protection extending 2029-2034

## LARGE, PROFITABLE MARKET

- FIRST & ONLY proprietary polymer bioresorbable scaffold for coronary artery disease: Fantom® made with Tyrocore™
- ~\$4 billion coronary stent market ripe for innovation

## COMMERCIALIZING FANTOM®

- European launch Q3 2017
  - Phase 1: Germany, Switzerland, Austria, Benelux, Denmark
  - Phase 2: Geographic expansion anticipated early 2018
- CE Mark Fantom Encore anticipated 2018

## INNOVATIVE PIPELINE

Multiple opportunities for growth:

- Product line expansion, geographic growth, and extended indications
- Peripheral product development below and above the knee

## SOLID FINANCIAL POSITION

- Listed on Australian stock exchange in 2010 (ASX: RVA.AX)
- Cash: \$24.1 million<sup>1</sup>
- Mkt Cap: \$210 million<sup>2</sup>
- Potential US stock market listing 2018; SEC registered

